APPLIED ORGANOMETALLIC CHEMISTRY, cilt.39, sa.3, 2025 (SCI-Expanded)
In this research, we designed phthalocyanine compounds that are thought to be used as potential acetyl/butyrylcholinesterase inhibitors in the treatment of Alzheimer's disease. First, phthalonitrile compound (PNM-CN), which is the precursor compound for phthalocyanines, was synthesized. Then, by cyclotetramerizing this compound, pyridine-substituted peripheral cobalt (PNM-CoPc), copper (PNM-CuPc), and manganese (PNM-MnClPc) phthalocyanine compounds were synthesized, and their structures were described using mass, NMR (except phthalocyanines), FT-IR, and UV-Vis (except phthalonitrile) spectroscopic techniques. Investigations were carried out into the new pyridine-substituted peripheral (PNM-Cu/Co/MnClPcs) phthalocyanines' in vitro inhibitory properties against butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE). With an IC50 of 5.95 +/- 2.12 mu M (AChE) and 0.74 +/- 0.01 mu M (BuChE), PNM-CuPc showed the most potent inhibitory effect against AChE and BuChE among all compounds.